

| | |
|---|--|
| Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515 | Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510 |
|---|--|

RECEIVED
SECRETARY OF THE

LOBBYING REPORT PH

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

| | | | |
|---|--|-----------------------------|----------------|
| 1. Registrant name | | | |
| Organization | Pfizer Inc | | |
| 2. Address <input type="checkbox"/> Check if different than previously reported | | | |
| Address1 | 325 7th Street, NW | | |
| City | Washington | | |
| State | DC | | |
| Zip Code | 20004 | | |
| Country | US | | |
| 3. Principal place of business (if different than line 2) | | | |
| City | State | Zip Code | Country |
| City | State/Zip or Country | | |
| 4a. Contact Name | b. Telephone number | c. E-mail | 5. Senate ID # |
| Prefix Full Name | | | |
| Mr. Anthony J. Principi | 202.783.7070 | anthony.principi@pfizer.com | 31326-1 |
| 7. Client Name | <input checked="" type="checkbox"/> Self | | 6. House ID # |
| Pfizer Inc | | | 3135400 |

TYPE OF REPORT 8. Year 2006 Midyear (January 1-June30) OR Year End (July 1-December)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇨ Termination Date _____

11. No Lobbying Acti

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

| | |
|---|--|
| <p align="center">12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇨ \$ _____</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p> | <p align="center">13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇨ \$ <u>4,500,000</u></p> <p>14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions of</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of Internal Revenue Code</p> |
|---|--|

Form C

Printed Name and Title Anthony J. Principi - Senior Vice President, Government Relations

0000200248

Registrant Name Pfizer Inc Client Name Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each cod** information as requested. Attach additional page(s) as needed.

15. General issue area code AGR - Agriculture (one per page)

16. Specific lobbying issues

HR 2206, Veterinary Workforce Expansion Act of 2005, increased funding for veterinary schools
 HR 2744, Agriculture Appropriations, pharmaceutical counterfeiting, importation
 S 914, Veterinary Workforce Expansion Act of 2005, increased funding for veterinary schools

17. House(s) of Congress and Federal agencies contacted None House Senate Other

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) |
|----------------------|---|
| Richard H. Bagger | |
| Catherine P. Bennett | |
| Kimberly Davis | |
| Dolly Judge | |
| Louis A. LaMarca | |
| Anthony J. Principi | Chairman, Base Realignment and Closure |
| Anne Wilson | |
| | |
| | |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 8/14/2006

1000200249

Registrant Name Pfizer Inc Client Name Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each cod** information as requested. Attach additional page(s) as needed.

15. General issue area code ANI - Animals (one per page)

16. Specific lobbying issues

S 1926, Animal Enterprise Terrorism Act, research safety
HR 4239, Animal Enterprise Terrorism Act, research safety
animal health (no bills)

17. House(s) of Congress and Federal agencies contacted None House Senate Other

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) |
|-------------|---|
| Ron Roberts | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

0000200250

Registrant Name Pfizer Inc

Client Name Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each cod** information as requested. Attach additional page(s) as needed.

15. General issue area code BUD - Budget/Appropriations (one per page)

16. Specific lobbying issues

H Con Res 95, Budget Reconciliation, pharmaceutical counterfeiting, importation
HR 2744, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies
Appropriations Act, 2006, pharmaceutical counterfeiting, importation
HR 2862, Science, State, Justice, Commerce, and Related Agencies Appropriations Act, 2006,
pharmaceutical counterfeiting, importation
HR 3010, Departments of Labor, Health and Human Services, and Education, and Related Agencies

17. House(s) of Congress and Federal agencies contacted None House Senate Other

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) |
|----------------------|---|
| Richard H. Bagger | |
| Catherine P. Bennett | |
| Kimberly Davis | |
| Dolly Judge | |
| Louis A. LaMarca | |
| Anthony J. Principi | Chairman, Base Realignment and Closure |
| Ron Roberts | |
| Myron Terry | |
| Anne Wilson | |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

House of Representatives
Senate

0000200251



Registrant Name Pfizer Inc Client Name Pfizer Inc

ADDENDUM for General Lobbying Issue Area BUD

16. Specific lobbying issues (continued from previous page)

Appropriations Act, 2006, pharmaceutical counterfeiting, importation
 S Con Res 18, Budget Reconciliation, pharmaceutical counterfeiting, importation
 S Con Res 83, Budget Resolution, non-interference

3000200252

Registrant Name Pfizer Inc Client Name Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each cod** information as requested. Attach additional page(s) as needed.

15. General issue area code CPT - Copyright/Patent/Trademark (one per page)

16. Specific lobbying issues

HR 328, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation
 HR 700, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation, patent issues
 S 109, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation
 S 334, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation, patent issues

17. House(s) of Congress and Federal agencies contacted None House Senate Other

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) |
|----------------------|---|
| Richard H. Bagger | |
| Kimberly Davis | |
| Catherine P. Bennett | |
| Dolly Judge | |
| Louis A. LaMarca | |
| Anthony J. Principi | Chairman, Base Realignment and Closure |
| Anne Wilson | |
| | |
| | |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

House of Representatives
Senate

1000200253

Registrant Name Pfizer Inc Client Name Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each cod** information as requested. Attach additional page(s) as needed.

15. General issue area code CSP - Consumer Issues/Safety/Protection (one per page)

16. Specific lobbying issues

HR 2090, The Food and Drug Administration Improvement Act of 2005, drug safety
 HR 3196, The Fair Access to Clinical Trials ("FACT") Act of 2005, drug safety
 HR 328, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation, drug safety
 HR 700, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation, patent issues

17. House(s) of Congress and Federal agencies contacted None House Senate Other

The Food and Drug Administration

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) |
|----------------------|---|
| Richard H. Bagger | |
| Catherine P. Bennett | |
| Kimberly Davis | |
| Louis A. LaMarca | |
| Anthony J. Principi | Chairman, Base Realignment and Closure |
| Anne Wilson | |
| | |
| | |
| | |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

0000200254

Registrant Name Pfizer Inc Client Name Pfizer Inc

ADDENDUM for General Lobbying Issue Area CSP

16. Specific lobbying issues (continued from previous page)

HR 870, The PhRMA Research and Manufacturers Accountability (PhRMA) Act, drug safety
S 109, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation
S 334, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importat
patent issues
S 470, The Fair Access to Clinical Trials ("FACT") Act of 2005, drug safety
S 930, Food and Drug Administration Safety Act of 2005, drug safety
HR 5156, Counterfeit Drug Prevention Act, pharmaceutical counterfeiting

0000200255

Registrant Name Pfizer Inc Client Name Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each cod** information as requested. Attach additional page(s) as needed.

15. General issue area code HCR - Health Issues (one per page)

16. Specific lobbying issues

HR 328, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation
 HR 700, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation, patent issues
 S 109, Pharmaceutical Market Access Act of 2005, pharmaceutical counterfeiting, importation
 S 334, Pharmaceutical Market Access and Drug Safety Act of 2005, pharmaceutical counterfeiting, importation, patent issues

17. House(s) of Congress and Federal agencies contacted None House Senate Other

Department of Health and Human Services
 Executive Office of the President
 Food and Drug Administration

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) |
|----------------------|---|
| Richard H. Bagger | |
| Catherine P. Bennett | |
| Christopher Carey | |
| Kimberly Davis | |
| Dolly Judge | |
| Louis A. LaMarca | |
| Anthony J. Principi | Chairman, Base Realignment and Closure |
| Ron Roberts | |
| Myron Terry | |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

0000200256

Registrant Name Pfizer Inc Client Name Pfizer Inc

ADDENDUM for General Lobbying Issue Area HCR

16. Specific lobbying issues (continued from previous page)

HR 3010, Department of Labor, Health and Human Service, and Education, and Related Agencies Appropri Act, 2006, access to prescription drugs
HR 3971, Social Services Emergency Relief and Recovery Act of 2005, access to prescription drugs
HR 5993, Authorized Generics Prohibition, authorized generics
S 3695, Authorized Generics Prohibition, authorized generics
HR 4157, Better Health Information System Act, health information technology
HR 4642, Wired for Health Act, health information technology
S1418, Wired for Health Act, health information technology
S 2300, Lower Priced Drug Act, generic drug access
HR 5005, Ryan White Care Act, reauthorization
S 2339, Ryan White Care Act, reauthorization

1000200257

Registrant Name Pfizer Inc Client Name Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each cod** information as requested. Attach additional page(s) as needed.

15. General issue area code MMM - Medicare/Medicaid (one per page)

16. Specific lobbying issues

HR 3010, Labor, HHS Appropriations, prescription drug benefit, price controls
 HR 712, Medicare Prescription Drug Sensibility Act, prescription drug benefit
 S 1932, Deficit Reduction Omnibus Reconciliation Act, prescription drug payment issues
 HR 5297, Improving Access to Medicare Part D Act of 2006, prescription drug benefit
 Medicare prescription drug benefit implementation (no bills)
 Medicaid rebates (no bills)

17. House(s) of Congress and Federal agencies contacted None House Senate Other

Department of Health and Human Services
 Executive Office of the President

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) |
|----------------------|---|
| Richard H. Bagger | |
| Catherine P. Bennett | |
| Christopher Carey | |
| Kimberly Davis | |
| Dolly Judge | |
| Louis A. LaMarca | |
| Anthony J. Principi | Chairman, Base Realignment and Closure |
| Ron Roberts | |
| Myron Terry | |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

0000200259

Registrant Name Pfizer Inc Client Name Pfizer Inc

ADDENDUM for General Lobbying Issue Area MMM

16. Specific lobbying issues (continued from previous page)

Medicaid coverage (no bills)

0000200260



Registrant Name Pfizer Inc Client Name Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each cod** information as requested. Attach additional page(s) as needed.

15. General issue area code SCI - Science/Technology (one per page)

16. Specific lobbying issues

HR 2122, The Project BioShield Act of 2003, pharmaceutical research and development, security

17. House(s) of Congress and Federal agencies contacted None House Senate Other

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) |
|------------------|---|
| Dolly Judge | |
| Louis A. LaMarca | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

0000200262

Registrant Name Pfizer Inc Client Name Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each cod** information as requested. Attach additional page(s) as needed.

15. General issue area code TAX - Taxation/Internal Revenue Code (one per page)

16. Specific lobbying issues

International repatriation tax (no bills)

17. House(s) of Congress and Federal agencies contacted None House Senate Other

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) |
|----------------------|---|
| Catherine P. Bennett | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

0000200263

Registrant Name Pfizer Inc Client Name Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each cod** information as requested. Attach additional page(s) as needed.

15. General issue area code TOR - Torts (one per page)

16. Specific lobbying issues

S 5, The Class Action Fairness Act of 2005, class action reform
S 852, The Fairness in Asbestos Injury Resolution Act of 2005, asbestos litigation

17. House(s) of Congress and Federal agencies contacted None House Senate Other

18. Name of each individual who acted as a lobbyist in this issue area

| Name | Covered Official Position (if applicable) |
|----------------------|---|
| Richard H. Bagger | |
| Catherine P. Bennett | |
| Kimberly Davis | |
| Anthony J. Principi | Chairman, Base Realignment and Closure |
| | |
| | |
| | |
| | |
| | |
| | |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

0000200264



Registrant Name Pfizer Inc

Client Name Pfizer Inc

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each cod information as requested. Attach additional page(s) as needed.

15. General issue area code TRD - Trade (Domestic & Foreign) (one per page)

16. Specific lobbying issues

HR 2862, Science, State, Justice Appropriations, market access
HR 3045, Dominican Republic-Central America-United States Free Trade Agreement Implementation Act, intellectual property, foreign price controls, market access restrictions
HR 3283, Agreement The United States Trade Rights Enforcement Act of 2005, intellectual property, market access, foreign price controls
S 307, Agreement The United States Trade Rights Enforcement Act of 2005, intellectual property, market

17. House(s) of Congress and Federal agencies contacted None House Senate Other

Department of Commerce
Department of State
Executive Office of the President
Office of the US Trade Representative

18. Name of each individual who acted as a lobbyist in this issue area

| | Name | Covered Official Position (if applicable) |
|--|----------------------|---|
| | Catherine P. Bennett | |
| | Christopher Carey | |
| | Dolly Judge | |
| | Louis A. LaMarca | |
| | Anthony J. Principi | Chairman, Base Realignment and Closure |
| | | |
| | | |
| | | |
| | | |

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

1000200265

Registrant Name Pfizer Inc Client Name Pfizer Inc

ADDENDUM for General Lobbying Issue Area TRD

16. Specific lobbying issues (continued from previous page)

access, foreign price controls
Intellectual property protection (no bills)
International pharmaceutical market access (no bills)
WTO accession and implementation issues (no bills)

0000200266

Registrant Name Pfizer Inc

Client Name Pfizer Inc

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

City

State/Zip

22. New general description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client

Michael D.

Boyd

Catherine P.

Bennett

Justin

McCarthy

ISSUE UPDATE

24. General lobbying issues that **no longer** pertain

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

| Name | Address | Principal place of Business (city and state or country) |
|------|---------|--|
| | | |

26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

| Name | Address | Principal place of business (city and state or country) | Amount of contribution for lobbying activities | Own perce client |
|------|---------|--|---|------------------------|
| | | | | |

28. Name of each previously reported foreign entity that **no longer** owns, **or** controls, **or** is affiliated with the registrant, c
affiliated organization

Signature _____

Date

8/14/2006

Printed Name and Title Anthony J. Principi - Senior Vice President, Government Relations

3000200267

